About Chongqing Pharmaceutical
Chongqing Pharmaceutical is a publicly listed company based in Chongqing (China) founded in 1950. It provides comprehensive drug discovery services to advance pharmaceutical solutions. It operates on a B2B model. Chongqing Pharmaceutical has completed 1 acquisition, including Tasly U.S. Its focus areas include Pharmaceuticals, Drug Discovery and Research Services. Its competitors include Viva Biotech and Qyuns Therapeutics; 1 of its 2 listed competitors has raised funding.
Company details
Chongqing Pharmaceutical operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, drug discovery, and research services. Provides comprehensive drug discovery services to advance pharmaceutical solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Chongqing, China
- Stage Public
- SectorsHealthcare
- Website cqphar.com/cqp
- Legal Name C.Q. Pharmaceutical Holding Co., Ltd. Class A
- Annual Revenue$11.76 B (USD)2.33as on Dec 31, 2025
- Net Profit$55.24 M (USD)36.65as on Dec 31, 2025
- EBITDA$219.97 M (USD)-13.5as on Dec 31, 2025
- Investments & Acquisitions
IPO & Listings of Chongqing Pharmaceutical
Chongqing Pharmaceutical is a publicly listed company on the SZSE with ticker symbol 000950 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Sep 1999
- Listed onSZSE: 000950
- Listed entityC.Q. Pharmaceutical Holding Co., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE0000010K0
- Share price5.30 CNY (+0.19% on the day) · 2026-10-14
- Market capitalisation9,060,595,958.00 CNY
- Price to earnings25.3
- EPS (diluted, trailing year)0.21 CNY
- Dividend yield1.13%
- Volume (last session)11,103,235
Financials of Chongqing Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 82.33B CNY | 386.7M CNY | 1.54B CNY |
| 2024 | 80.46B CNY | 283.0M CNY | 1.78B CNY |
| 2023 | 78.27B CNY | 624.6M CNY | 2.35B CNY |
| 2022 | 67.71B CNY | 952.3M CNY | 2.64B CNY |
| 2021 | 62.42B CNY | 1.01B CNY | 2.54B CNY |
Detailed financial statements for Chongqing Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chongqing Pharmaceutical
Chongqing Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tasly U.S..
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical, biologic, and nutraceutical products are provided by Tasly. | taslyus.com | Rockville, United States | 2006 | Jun 2020 | $210.05M |
Complete acquisition details for Chongqing Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chongqing Pharmaceutical
3 dated milestones of Chongqing Pharmaceutical across 70 years, from founding to its latest funding, stage changes and deals.
- Founded Chongqing Pharmaceutical is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Tasly U.S..
Competitors of Chongqing Pharmaceutical
Chongqing Pharmaceutical has 2 listed competitors in our database, 1 of them funded. They include Viva Biotech and Qyuns Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vivabiotech.com | 2006 | Shanghai, China | Drug discovery and development research services are provided. | |||
| qyuns.net | 2015 | Taizhou, China | $66.35M | Drug development services are provided to the biopharma sector. |
Detailed competitors of Chongqing Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chongqing Pharmaceutical
Complete news archive for Chongqing Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chongqing Pharmaceutical
Chongqing Pharmaceutical was founded in 1950.
Chongqing Pharmaceutical is headquartered in Chongqing, China.
Annual revenue of Chongqing Pharmaceutical is $11.76B as on Dec 31, 2025.
Chongqing Pharmaceutical operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, drug discovery, and research services. Provides comprehensive drug discovery services to advance pharmaceutical solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Chongqing Pharmaceutical's top competitors include Viva Biotech and Qyuns Therapeutics.
Yes, Chongqing Pharmaceutical is publicly traded on SZSE under the ticker symbol 000950.
Chongqing Pharmaceutical has made 1 acquisition, including Tasly U.S.